Clinical Policy: Mipomersen (Kynamro)
Reference Number: CP.PHAR.284
Effective Date: 10.16
Last Review Date: 02.19
Line of Business: Commercial, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Mipomersen (Kynamro®) is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis.

FDA Approved Indication(s)
Kynamro is indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Limitation(s) of use:
• The safety and effectiveness of Kynamro have not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).
• The effect of Kynamro on cardiovascular morbidity and mortality has not been determined.
• The use of Kynamro as an adjunct to LDL apheresis is not recommended.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Kynamro is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Homozygous Familial Hypercholesterolemia (must meet all):
      1. Diagnosis of HoFH defined as one of the following (a, b or c):
         a. Genetic mutation indicating HoFH (e.g., mutations in low density lipoprotein receptor [LDLR] gene, proprotein convertase subtilisin kexin 9 (PCSK9) gene, apo B gene, low density lipoprotein receptor adaptor protein 1 [LDLRAP1] gene);
         b. Treated LDL-C ≥ 300 mg/dL or non-HDL-C ≥ 330 mg/dL;
         c. Untreated LDL-C ≥ 500 mg/dL, and one of the following (i or ii):
            i. Tendinous or cutaneous xanthoma prior to age 10 years;
            ii. Evidence of HeFH in both parents (e.g., documented history of elevated LDL-C ≥ 190 mg/dL prior to lipid-lowering therapy);
      2. Prescribed by or in consultation with a cardiologist, endocrinologist or lipid specialist;
      3. Age ≥ 18 years;
4. Documentation of recent (within the last 30 days) LDL-C ≥ 70 mg/dL;
5. Member has been adherent to a high intensity statin (see Appendix D) regimen for at least the last 4 months, unless one of the following applies (a, b, or c):
   a. Statin therapy is contraindicated per Appendix E;
   b. Member has been adherent to a moderate intensity statin (see Appendix D) regimen for at least the last 4 months due to one of the following (i or ii):
      i. Intolerance to two high intensity statins;
      ii. A statin risk factor (see Appendix F);
   c. Member is unable to take a high or moderate intensity statin due to one of the following (i or ii):
      i. Intolerance to two high and two moderate intensity statins;
      ii. A statin risk factor (see Appendix F) and history of intolerance to two moderate intensity statins;
6. Member has been adherent to ezetimibe therapy used concomitantly with a statin at the maximally tolerated dose for at least the last 4 months, unless contraindicated per Appendix E or member has a history of ezetimibe intolerance (e.g., associated diarrhea or upper respiratory tract infection);
7. Failure of Repatha®, unless contraindicated or clinically significant adverse effects are experienced;  
   *Prior authorization is required for Repatha
8. Treatment plan does not include coadministration with Juxtapid®, Praluent®, Repatha®;
9. Dose does not exceed 200 mg per week.

**Approval duration: 6 months**

**B. Other diagnoses/indications**
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Homozygous Familial Hypercholesterolemia (must meet all):**
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by lab results within the last 3 months showing an LDL-C reduction since initiation of Kynamro therapy;
3. If request is for a dose increase, new dose does not exceed 200 mg per week.

**Approval duration: 12 months**

**B. Other diagnoses/indications (1 or 2):**
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less); or**
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.
III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   ALT: Alanine transaminase  LDL-C: low density lipoprotein cholesterol
   apo B: apolipoprotein B  LDLR: low density lipoprotein receptor
   FDA: Food and Drug Administration  LDLRAP1: low density lipoprotein receptor adaptor protein 1
   HDL-C: high-density lipoprotein cholesterol  PCSK9: proprotein convertase subtilisin kexin 9
   HeFH: heterozygous familial hypercholesterolemia  TC: total cholesterol
   HoFH: homozygous familial hypercholesterolemia  ULN: upper limit of normal

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/ Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>ezetimibe/ simvastatin (Vytorin®)</td>
<td>10/40 mg PO QD</td>
<td>10 mg-40 mg/day (use of the 10/80 mg dose is restricted to patients who have been taking simvastatin 80 mg for 12 months or more without evidence of muscle toxicity)</td>
</tr>
<tr>
<td>ezetimibe (Zetia®)</td>
<td>10 mg PO QD</td>
<td>10 mg/day</td>
</tr>
<tr>
<td>atorvastatin (Lipitor®)</td>
<td>40 mg PO QD</td>
<td>80 mg/day</td>
</tr>
<tr>
<td>rosuvastatin (Crestor®)</td>
<td>5 - 40 mg PO QD</td>
<td>40 mg/day</td>
</tr>
<tr>
<td>Repatha® (evolocumab)</td>
<td>420 mg SC once monthly</td>
<td>420 mg/month</td>
</tr>
</tbody>
</table>

   Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

   Appendix C: Contraindications/Boxed Warnings
   • Contraindication(s):
     o Moderate or severe hepatic impairment (Child-Pugh B or C)
     o Active liver disease, including unexplained persistent elevations of serum transaminases
   • Boxed warning(s): risk of hepatotoxicity
### Appendix D: High and Moderate Intensity Daily Statin Therapy for Adults

<table>
<thead>
<tr>
<th>Therapy Level</th>
<th>Daily dose shown to lower LDL-C, on average, by</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High Intensity Statin Therapy</strong></td>
<td>≥50%</td>
<td>Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg</td>
</tr>
<tr>
<td><strong>Moderate Intensity Statin Therapy</strong></td>
<td>30% to 50%</td>
<td>Atorvastatin 10-20mg, Fluvastatin XL 80 mg, Fluvastatin 40 mg 2x/day, Lovastatin 40 mg, Pitavastatin 2-4 mg, Pravastatin 40-80 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg</td>
</tr>
<tr>
<td><strong>Low Intensity Statin Therapy</strong></td>
<td>&lt;30%</td>
<td>Simvastatin 10 mg, Pravastatin 10–20 mg, Lovastatin 20 mg, Fluvastatin 20–40 mg, Pitavastatin 1 mg</td>
</tr>
</tbody>
</table>

### Appendix E: Statin and Ezetimibe Contraindications

**Statin**
- Decompensated liver disease (development of jaundice, ascites, variceal bleeding, encephalopathy)
- Laboratory-confirmed acute liver injury or rhabdomyolysis resulting from statin treatment
- Pregnancy, actively trying to become pregnant, or nursing
- Immune-mediated hypersensitivity to the HMG-CoA reductase inhibitor drug class (statins) as evidenced by an allergic reaction occurring with at least TWO different statins

**Ezetimibe**
- Moderate or severe hepatic impairment [Child-Pugh classes B and C]
- Hypersensitivity to ezetimibe (e.g., anaphylaxis, angioedema, rash, urticaria)

### Appendix F: Statin Risk Factors

**Statin Risk Factors**
- Multiple or serious comorbidities, including impaired renal or hepatic function
- Unexplained alanine transaminase (ALT) elevations > 3 times upper limit of normal, or active liver disease
- Concomitant use of drugs adversely affecting statin metabolism
- Age > 75 years, or history of hemorrhagic stroke
Statin Risk Factors

- Asian ancestry

Appendix G: General Information

- The safety and effectiveness of Kynamro have not been established in pediatric patients.
- The effect of Kynamro on cardiovascular morbidity and mortality has not been determined.
- The safety and effectiveness of Kynamro have not been established in pediatric patients.
- There is a black box warning on the package labeling for Kynamro regarding the risk of hepatotoxicity. In the Kynamro HoFH clinical trial 4 (12%) of the 34 patients treated with Kynamro compared to 0% of the 17 placebo-treated patients had an elevation in alanine transaminase (ALT) at least 3x upper limit of normal (ULN); and, 3 (9%) of those treated with Kynamro compared to 0% treated with placebo had at least one elevation in ALT of at least 5x ULN. Because of the risk of hepatotoxicity, Kynamro is available only through a Risk Evaluation and Mitigation Strategy (REMS) program.
- Because of the risk of hepatotoxicity, Kynamro is available only through a Risk Evaluation and Mitigation Strategy (REMS) program.
- Low density lipoprotein receptor adaptor protein 1 (LDLRAP1) gene is also known as autosomal recessive hypercholesterolemia (ARH) adaptor protein 1 gene.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>HoFH</td>
<td>200 mg SC once per week</td>
<td>200 mg/week</td>
</tr>
</tbody>
</table>

VI. Product Availability

Pre-filled syringe: 200 mg/mL

VII. References

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.
The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.